ExonHit, BioMerieux Call off Colon Cancer Collaboration | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics and BioMerieux are discontinuing their collaboration aimed at identifying biomarkers and developing tests for colon cancer, ExonHit announced today.

The decision reportedly comes on the heels of a recent review of scientific and clinical data from the colon cancer screening research program.

However, the companies plan to continue working together to find biomarkers and develop tests for early-stage prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.